Navigation Links
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
Date:11/16/2009

Anti-Fungal, Additional Mycobacterial Indications Among Those Targeted

ROCKVILLE, Md., Nov. 16 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

SQ109, currently completing a Phase IB safety study in humans under its original tuberculosis IND, is a new chemical entity with broad antibiotic potential. It was co-discovered by scientists at Sequella and at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under an earlier Cooperative Research and Development Agreement. Sequella previously negotiated from NIH worldwide exclusive rights for SQ109's use against tuberculosis.

The new agreement will allow Sequella to pursue additional infectious disease indications targeting fungi and a variety of nontubercular Mycobacteria.

Dr. Carol Nacy, CEO of Sequella, said, "We see tremendous promise in the future of SQ109, both as part of a new tuberculosis regimen and as a therapeutic active against other infectious agents. IND-directed studies in support of these new indications are underway."

About SQ109

SQ109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. SQ109 is due to begin a Phase 1B study to assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

About Sequ
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
4. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
5. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License
11. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) September 30, 2014 New applications ... arrangements that have evolved in nature over millennia are ... bioinspired materials for applications in biophotonics in the ... . The journal is published by SPIE, the international ... Library. Several of the peer-reviewed articles are accessible via ...
(Date:10/1/2014)... -- This report analyzes the worldwide markets ... the following Product Segments: Proteases, Polymerases, Carbohydrases, ... also analyzed are Pharmaceuticals & Diagnostics, Research/Biotechnology, ... separate comprehensive analytics for the US, Canada, ... America. Annual estimates and forecasts are provided ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market is ... increased acceptance of new filtration technologies in end users ... also catalyzing the growth of laboratory filtration market. , ... at a strong CAGR during the forecast period of ... by 2019. The market is mainly driven by the ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced ... Parshall, J.D. to Chief Operating Officer,effective immediately. Ms. ... is a Director of the Company., "This ... Lynne,s responsibilities at Isis," commented Stanley Crooke, M.D.,Ph.D., ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of ... Deval L. Patrick of the Commonwealth of,Massachusetts, ... Official Delegation, paid a visit to the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Massachusetts ...
... Pharmaceutical announced,today that the Avon Foundation Breast Cancer ... to conduct multicenter clinical studies,focused on measuring levels ... and tissue samples from breast cancer patients. Results ... a blood test that would,enable early detection of ...
Cached Biology Technology:Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 2Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 3A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Synthetic sperm protein raises the chance for successful in vitro fertilization 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Environmental Research UFZ present CLIMBER: Climatic niche ... dataset on the climatic niche characteristics of 397 European ... information provided in this dataset is of great relevance ... of high quality standards and open access, data ready ...
... fins with self-adaptive flaps, the feathers on a diving peregrine ... a study published in PLOS ONE on February ... and Fluid Dynamics in Germany and colleagues., Peregrine falcons are ... to 200 miles per hour when diving. Scientists studying the ...
... 6, 2014 -- Advances in neonatal care for very ... for these fragile infants. However, preterm infants have ... serious lung disease, which is a major cause of ... scheduled for publication in The Journal of Pediatrics ...
Cached Biology News:Unique new dataset CLIMBER: Climatic niche characteristics of the butterflies in Europe 2Stem cells to treat lung disease in preterm infants 2
Recombinant Mouse Wnt-3a...
... at least 20 structurally and functionally related ... superfamily. BMPs were originally identified as protein ... are also involved in embryogenesis and morphogenesis ... the growth, differentiation, chemotaxis and apoptosis of ...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
RABBIT ANTI HUMAN CHYMOTRYPSIN...
Biology Products: